Use of Baricitinib in Patients with Moderate and Severe COVID-19

Clin Infect Dis. 2020 Jun 29;ciaa879. doi: 10.1093/cid/ciaa879. Online ahead of print.

Abstract

Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.